Company Overview

Caris Life Sciences, Inc. (CAI) is a privately held biotechnology and precision oncology company that develops and commercializes molecular profiling solutions to support cancer diagnosis, prognosis, and treatment selection. The company operates at the intersection of precision medicine, molecular diagnostics, bioinformatics, and pharmaceutical research, with a focus on enabling data-driven oncology care and drug development. Its offerings are used by oncologists, pathologists, biopharmaceutical companies, and research institutions.

Caris’s core business centers on comprehensive tumor profiling that integrates genomic, transcriptomic, proteomic, and digital pathology data. The company differentiates itself through large-scale clinico-genomic datasets, advanced artificial intelligence and machine learning analytics, and an integrated laboratory and informatics platform. Founded in 2008, Caris evolved from a diagnostics-focused laboratory into a broader data and technology company supporting both clinical decision-making and life sciences research, with increasing emphasis on biopharma partnerships and real-world evidence generation.

Business Operations

Caris generates revenue primarily through its Molecular Profiling Services business, which provides tumor testing services for clinical use, and its Biopharma Solutions business, which licenses data, analytics, and services to pharmaceutical and biotechnology companies. Molecular profiling services are ordered by physicians and reimbursed through a mix of third-party payors, government programs, and self-pay arrangements, while biopharma revenue is driven by long-term strategic collaborations and research contracts.

Operationally, Caris controls CLIA- and CAP-certified laboratories, proprietary sequencing and imaging workflows, and a cloud-based data and analytics platform. The company integrates next-generation sequencing, whole-exome and whole-transcriptome analysis, immunohistochemistry, and advanced digital pathology. Caris also maintains partnerships with academic medical centers and biopharmaceutical companies, though specific commercial terms of many agreements are not publicly disclosed. Data inconclusive based on available public sources regarding the full financial breakdown by segment due to private company status.

Strategic Position & Investments

Caris’s strategy emphasizes scaling its multimodal molecular dataset, expanding artificial intelligence capabilities, and deepening biopharma collaborations to support drug discovery, clinical trial design, and biomarker development. The company has invested heavily in computational infrastructure and data science to enable predictive modeling and real-world evidence generation, positioning itself as both a diagnostics provider and a data partner to the life sciences industry.

The company has completed multiple strategic acquisitions and technology integrations over its history to enhance sequencing, imaging, and informatics capabilities; however, not all transaction values or structures are publicly available. Caris is also known to invest in emerging areas such as whole-genome analysis, RNA-based insights, and AI-driven pathology. While Caris has explored public market options in the past, including discussions around a potential IPO, no completed public listing has been verified in current filings.

Geographic Footprint

Caris is headquartered in Irving, Texas, and maintains primary laboratory and operational facilities in the United States. Its molecular profiling services are offered nationwide, supporting oncologists and health systems across major U.S. markets. The company’s U.S. footprint represents the majority of its clinical testing volume and revenue generation.

Internationally, Caris supports global biopharmaceutical clients and research collaborations, with commercial reach extending into Europe, Asia-Pacific, and other regions through data licensing and clinical trial support activities. While Caris does not publicly disclose extensive international laboratory operations, its datasets and analytical services are used in multinational drug development programs, giving it indirect operational influence across multiple continents.

Leadership & Governance

Caris was founded by David D. Halbert, who has played a central role in shaping the company’s long-term vision around precision oncology and data-driven medicine. The leadership team emphasizes scientific rigor, long-term data asset development, and partnerships with both clinicians and biopharmaceutical companies to improve cancer outcomes and accelerate therapeutic innovation.

Key executives include:

• David D. Halbert – Chairman, Founder, and Chief Executive Officer
• George W. Sledge Jr., MD – Chief Medical Officer
• Rami Katkhuda, MD – Chief Medical Officer (Life Sciences)
• Jeff Brown – Chief Financial Officer
• Chad Creighton, PhD – Chief Genomics Officer

The governance structure reflects a founder-led model with strong executive oversight, supported by scientific and clinical leadership drawn from oncology, genomics, and pharmaceutical research backgrounds.